Novelix Pharmaceuticals Sees Strong FY26 Growth, Revenue ₹132 Cr, Profit ₹2.56 Cr

Revenue ₹132.34 crore, Net Profit ₹2.56 crore

Reader Takeaway: Strong revenue and profit growth driven by scaled operations; monitor working capital management.

What just happened

Novelix Pharmaceuticals Limited announced its audited financial results for the year ended March 31, 2026. The company reported a substantial increase in revenue, reaching ₹132.34 crore, a significant jump from ₹30.73 crore in the previous fiscal year. Net profit also saw a sharp rise, growing to ₹2.56 crore from ₹0.08 crore in FY2025. Additionally, the company completed the allotment of 28.10 lakh equity shares following the conversion of warrants, raising ₹4.22 crore.

Why this matters

The strong financial performance indicates successful scaling of Novelix Pharmaceuticals' operations. The multi-fold increase in both revenue and profit suggests market acceptance and effective business expansion. The preferential allotment also strengthens the company's equity base and provides capital infusion.

The backstory

In FY2025, Novelix Pharmaceuticals had reported significantly lower revenue of ₹30.73 crore and a net profit of just ₹0.08 crore. The current fiscal year's results show a dramatic turnaround and growth trajectory.

What changes now

Investors can expect the company to focus on sustaining this growth momentum. The capital raised from the warrant conversion will likely support ongoing operations and future expansion plans. The company's ability to manage its increased working capital requirements will be crucial.

Risks to watch

A key concern highlighted is the negative operating cash flow of ₹-22.39 crore for FY2026. This is primarily attributed to a significant increase in trade receivables, indicating that the company is locking up substantial capital in working capital to fuel its growth.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

Total Revenue FY2026: ₹132.34 crore (₹13,233.88 lakh)
Net Profit FY2026: ₹2.56 crore (₹255.66 lakh)
Net Profit FY2025: ₹0.08 crore (₹8.45 lakh)
Operating Cash Flow FY2026: ₹-22.39 crore (₹-2,238.91 lakh)
Equity shares allotted on warrant conversion: 28.10 lakh
Issue price per share (warrant conversion): ₹20
Capital raised from warrants: ₹4.22 crore

What to track next

Investors should closely monitor the company's working capital management, specifically the conversion of trade receivables into cash. Continued revenue growth and improved operating cash flow will be key indicators of sustainable performance.